In Reply In designing this trial,1 we sought to test 2 treatments with known effectiveness for urinary symptoms and implement them as one would in clinical practice. To optimize the drug therapy, we chose to use both an antimuscarinic and an α-adrenergic antagonist (α-blocker), based on evidence that using both drugs can yield better outcomes than either one alone.2 We had previously shown the behavioral intervention to be useful for urinary symptoms in men.3 The study objective was to determine whether combining behavioral and drug therapies improves outcomes compared with each therapy alone for overactive bladder in men and to compare 3 sequences for implementing combined therapy. Our study outcomes focused on the overactive bladder symptoms of urgency, frequency, nocturia, and urge urinary incontinence (UI).
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Johnson TM, Burgio KL, Kraus SR. Considering the Effect of Combining α-Blockers With Bladder Antimuscarinics in Treatment of Overactive Bladder Symptoms—Reply. JAMA Intern Med. Published online May 11, 2020. doi:10.1001/jamainternmed.2020.1253
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: